Vimarsana
Biggest News Aggregation in the World

Page 19 - Ellen Rose News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ellen Rose. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ellen Rose Today - Breaking & Trending Today

Prothena Presents Phase 1 Study Results of PRX004 in Oral Presentation at AAN 2021 - Vimarsana News

Prothena Presents Phase 1 Study Results of PRX004 in Oral Presentation at AAN 2021

Prothena Presents Phase 1 Study Results of PRX004 in Oral Presentation at AAN 2021 Nachrichtenquelle: globenewswire  |  18.04.2021, 21:05  |  113   |  0  Slowing of neuropathy progression for all 7 evaluable patients, evidenced by a +1.29 point mean change in NIS, was more favorable than expected progression of +9.2 points Improvement in neuropathy for 3 of these 7 evaluable patients demonstrated by a mean change in NIS of -3.33 points Improvement in cardiac function ...

Investegate |Prothena Corporation plc Announcements | Prothena Corporation plc: Prothena Presents Phase 1 Study Results of PRX004 in Oral Presentation at AAN 2021 - Vimarsana News

Investegate |Prothena Corporation plc Announcements | Prothena Corporation plc: Prothena Presents Phase 1 Study Results of PRX004 in Oral Presentation at AAN 2021

Prothena Presents Phase 1 Study Results of PRX004 in Oral Presentation at AAN 2021 Slowing of neuropathy progression for all 7 evaluable patients, evidenced by a +1.29 point mean change in NIS, was more favorable than expected progression of +9.2 points Improvement in neuropathy for 3 of these 7 evaluable patients demonstrated by a mean change in NIS of -3.33 points Improvement in cardiac function for all 7 evaluable patients demonstrated by a decrease in global longitudinal strain (GLS) Emerging Science Oral Presentation today at AAN 2021 DUBLIN, Ireland, April 18, 2021 (GLOBE NEWSWIRE)...

Prothena Announces PRX004 Phase 1 Study Results Selected for Emerging Science Oral Presentation ... - Vimarsana News

Prothena Announces PRX004 Phase 1 Study Results Selected for Emerging Science Oral Presentation ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Prothena Announces PRX004 Phase 1 Study Results Selected for Emerging Science Oral Presentation ... Prothena Corporation plcApril 15, 2021 GMT DUBLIN, Ireland, April 15, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, today announced that results from its Phase 1 study of PRX004 in ATTR amyloidosis have been ...

Source: apnews.com
Investegate |Prothena Corporation plc Announcements | Prothena Corporation plc: Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Vimarsana News

Investegate |Prothena Corporation plc Announcements | Prothena Corporation plc: Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) DUBLIN, Ireland, April 07, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, today announced that in connection with hiring Dr. Hideki Garren as Prothena’s Chief Medical Officer, the compensation committee of the Company’s board of directors granted Dr. Garren, an option to purchase 250,000 ordinary shares of the Company. Suc...

Prothena Corporation plc: Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Vimarsana News

Prothena Corporation plc: Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Prothena Corporation plc: Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) DUBLIN, Ireland, April 07, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, today announced that in connection with hiring Dr. Hideki Garren as Prothena's Chief Medical Officer, the compensation committee of the Company's board of directors granted Dr. Garren, an option to purchase 250,000 ordinary shares...